protein

alpha-Synuclein 61-140, Human, Recombinant, E Coli

MBS203007

0.1 mg

255 USD

Recombinant Protein

alpha-Synuclein 61-140, Human, Recombinant, E Coli

alpha-Synuclein 61-140

SNCA; NACP; PARK1; alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; Alpha synuclein; Alpha-synuclein isoform NACP140; alphaSYN; MGC105443; MGC110988; MGC127560; MGC64356; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid; precursor of PARK 1; PARK 4; PARK4; Parkinson disease familial 1; PD 1; PD1; Synuclein alpha

alpha-synuclein isoform NACP140; Alpha-synuclein; alpha-synuclein; non A-beta component of AD amyloid; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP

SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP

SYUA_HUMAN

140

MEQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA

> 95% by SDS - PAGE

Liquid. In 20 mM Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl

1 mg/ml (determined by BCA assay)

Can be stored at 4 degree C short term (1-2 weeks). For long term storage, aliquot and store at -20 degree C or -70 degree C. Avoid repeated freezing and thawing cycles.

SDS-PAGE

Antigen Species: Human

Expression System: E Coli

Neuroscience

A deletion mutant of alpha-synuclein (amino acids 61-140). Syn61-140 was overexpressed in E. coli and was purified to apparent homogeneity by taking advantage of the thermosolubility of protein and by using conventional column chromatography techniques. Additional amino acid(Met) is attached at the N-terminus.

Park SM., et al. (2002) Blood. 100(7):2506-14. Park SM., et al. (2002) Biochemistry. 41(12):4137-46.

4507109

NP_000336.1

NM_000345.3

8.4 kDa (81 aa), confirmed by MALDI-TOF. (Molecular weight on SDS-PAGE will appear higher)

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; fibril; extracellular region; terminal button; cell cortex; inclusion body; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; perinuclear region of cytoplasm; axon; cytoplasm; plasma membrane; ribosome; nucleus; cell junction. Molecular Function: identical protein binding; protein domain specific binding; zinc ion binding; histone binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; magnesium ion binding; beta-tubulin binding; protein N-terminus binding; phosphoprotein binding; Hsp70 protein binding; oxidoreductase activity; calcium ion binding; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; tau protein binding; fatty acid binding; alpha-tubulin binding. Biological Process: regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; positive regulation of endocytosis; response to lipopolysaccharide; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; negative regulation of monooxygenase activity; negative regulation of caspase activity; negative regulation of transcription from RNA polymerase II promoter; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of histone acetylation; negative regulation of dopamine uptake; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; phospholipid metabolic process; receptor internalization; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; regulation of glutamate secretion; negative regulation of microtubule polymerization; regulation of macrophage activation; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential. Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body

0.1 mg

255 USD

0.5 mg

535